‍

Ophthalmic drug development depends on two critical pillars most trials still struggle to deliver:

1. Standardized imaging data and endpoints across sites
2. The ability to predict who progresses and when

The first problem is solved using RetinAI Discovery^®. Now CE-marked under MDR, our RetinAI OCT Atlas^® model delivers a device-agnostic AI pipeline for automated, standardized layer and fluid segmentation across Diabetic Retinopathy, Glaucoma and AMD. Its accuracy was validated in the DILL study against three independent expert graders. 

The second challenge represents where the future of ophthalmic research is heading. Our research use only, GA progression prediction model builds on RetinAI OCT Atlas^® as its certified segmentation foundation, then adds a predictive layer to forecast outer retina atrophy up to 4 years ahead, including in early-stage patients with small lesions. For Pharma teams running GA trials or building research pipelines, the data is directly relevant. 

Together, these two powerful AI tools deliver a comprehensive, end-to-end pipeline for precision medicine: certified, multi-disease quantification for clinical endpoints today, and predictive modeling for the research that shapes tomorrow’s trials.

Here is what you will learn:

• RetinAI OCT Atlas^®, Standardized, Device-Agnostic Quantification
  ‍Discover how the CE-marked RetinAI OCT Atlas^® model delivers consistent automated layer, fluid and biomarker segmentation across DR, Glaucoma & AMD - on Heidelberg, Topcon, Zeiss and other major OCT platforms. For Pharma teams, this means standardized biomarker endpoints across every site in your trial, without hardware constraints or manual normalization.

• The DILL Study, Clinical validation across 3 disease areas 
  ‍The DILL Study validated RetinAI OCT Atlas^® against three independent expert graders across DR, Glaucoma and AMD. The automated analysis met all literature-defined performance targets for critical biomarkers. Processing time? Under one second per scan. 

• Forecasting GA Progression Up to 4 Years, the research layer (RUO)
  ‍For GA specifically, RetinAI OCT Atlas^® is the certified foundation of a broader predictive pipeline. Our research use only, GA Progression Prediction* model takes that segmentation output and forecasts outer retina atrophy across ONL+HFL, MZ, EZ+OPR+IZ, and RPE layers up to 4 years ahead.  Learn how this model maintains high predictive accuracy even in early-stage patients with small lesions, where prediction matters most for trial designs and patient selection.

^*GA Progression Prediction and FAF functionalities are Research Use Only (RUO). They are not intended for clinical use and must not be used for diagnosis, prognosis, patient management, treatment decisions, or other clinical decision-making.

Register today! 👇

‍

Unable to join live? No problem - registered attendees will receive a link to the session recording! For questions or additional information, please reach out to us at events@retinai.com.

Meet our Speakers:

• David Romero-Bascones, Research Engineer at RetinAI
• Guilherme Moreira Aresta, Research Engineer at RetinAI
• ‍Natasa Jovic, VP Marketing Strategy & Research Partnerships